First-Line Treatment with Bevacizumab and Platinum Doublet Combination in Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Cohort Study in US Oncology Community Practices

BACKGROUND: Real-world evidence is lacking on the impact of bevacizumab added to carboplatin/paclitaxel (Bev + CP) therapy versus CP alone for patients with non-squamous non-small cell lung cancer (NS-NSCLC), particularly in those excluded from clinical trials. METHODS: This is a retrospective elect...

Descripción completa

Detalles Bibliográficos
Autores principales: Lunacsek, Orsolya E., Ravelo, Arliene, Coutinho, Anna D., Hazard, Sebastien J., Green, Mark R., Willey, Joanne, Eaddy, Michael, Goertz, Hans-Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042946/
https://www.ncbi.nlm.nih.gov/pubmed/27747837
http://dx.doi.org/10.1007/s40801-016-0090-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042946/
https://www.ncbi.nlm.nih.gov/pubmed/27747837
http://dx.doi.org/10.1007/s40801-016-0090-5

Ejemplares similares